BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21775097)

  • 21. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
    Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G
    Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
    Shin SJ; Chun SH; Kim KO; Kim MK; Lee KH; Hyun MS; Cho HS
    Jpn J Clin Oncol; 2005 Oct; 35(10):622-5. PubMed ID: 16172172
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Translocation (3;8)(q26;q24): a recurrent chromosomal abnormality in myelodysplastic syndrome and acute myeloid leukemia.
    Lin P; Medeiros LJ; Yin CC; Abruzzo LV
    Cancer Genet Cytogenet; 2006 Apr; 166(1):82-5. PubMed ID: 16616115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
    J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders.
    Bowcock SJ; Rassam SM; Lim Z; Ward SM; Ryali MM; Mufti GJ
    Br J Haematol; 2006 Jul; 134(2):242-3. PubMed ID: 16846486
    [No Abstract]   [Full Text] [Related]  

  • 28. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: possible role of cytarabine.
    Arana-Yi C; Block AW; Sait SN; Ford LA; Barcos M; Baer MR
    Leuk Res; 2008 Jul; 32(7):1043-8. PubMed ID: 18093651
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
    Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
    Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
    Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.
    Tam C; Seymour JF; Brown M; Campbell P; Scarlett J; Underhill C; Ritchie D; Bond R; Grigg AP
    Haematologica; 2005 May; 90(5):700-2. PubMed ID: 15921393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy-associated genetic aberrations in patients treated for non-Hodgkin lymphoma.
    Basecke J; Podleschny M; Becker A; Seiffert E; Schwiers I; Schwiers R; Haase D; Glass B; Schmitz N; Trumper L; Griesinger F
    Br J Haematol; 2008 Apr; 141(1):52-9. PubMed ID: 18324966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapy-related myelodysplastic syndrome/acute myeloid leukemia following fludarabine therapy for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Thai patients.
    Niparuck P; Kanoksil W; Chuncharunee S; Boonsakan P; Ungkanont A; Angchaisuksiri P; Karntisaviwat K; Apilugsanachit A; Rerkamnuatchoke B; Jootar S; Nitiyanant P; Atichartakarn V
    Leuk Lymphoma; 2010 Nov; 51(11):2120-5. PubMed ID: 20846095
    [No Abstract]   [Full Text] [Related]  

  • 36. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
    Coso D; Costello R; Cohen-Valensi R; Sainty D; Nezri M; Gastaut JA; Bouabdallah R
    Ann Oncol; 1999 Mar; 10(3):362-3. PubMed ID: 10355587
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report.
    Heyn R; Khan F; Ensign LG; Donaldson SS; Ruymann F; Smith MA; Vietti T; Maurer HM
    Med Pediatr Oncol; 1994; 23(2):99-106. PubMed ID: 8202048
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
    Tsimberidou AM; Kantarjian HM; Estey E; Cortes JE; Verstovsek S; Faderl S; Thomas DA; Garcia-Manero G; Ferrajoli A; Manning JT; Keating MJ; Albitar M; O'Brien S; Giles FJ
    Leukemia; 2003 Jun; 17(6):1100-3. PubMed ID: 12764375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute myeloid leukemia secondary to a myelodysplastic syndrome with t(3;3) (q21;q26) in an HIV patient treated with chemotherapy and highly active antiretroviral therapy.
    Breccia M; Gentile G; Martino P; Petti MC; Russo E; Mancini M; Alimena G
    Acta Haematol; 2004; 111(3):160-2. PubMed ID: 15034238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
    Carney DA; Seymour JF
    Leuk Lymphoma; 2010 Nov; 51(11):1957-9. PubMed ID: 20858101
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.